摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

别-育亨宾碱 | 522-94-1

中文名称
别-育亨宾碱
中文别名
别育享宾
英文名称
(+/-)-alloyohimbine
英文别名
allo-Yohimbine;methyl (1S,15S,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
别-育亨宾碱化学式
CAS
522-94-1
化学式
C21H26N2O3
mdl
——
分子量
354.449
InChiKey
BLGXFZZNTVWLAY-FJDMERLMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    98-99°; anhydrous form melts at 135-140°
  • 比旋光度:
    D19 +84° (c = 0.40 in pyridine)
  • LogP:
    2.200 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    65.6
  • 氢给体数:
    2
  • 氢受体数:
    4

SDS

SDS:39d060c79401426f0ad1adf40ff3dcf6
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    —— 19,20-didehydroyohimban-17-one 81750-86-9 C19H20N2O 292.381
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    1H-1-苯氮杂卓-1-乙酸,3-氨基-2,3,4,5-四氢-a-甲基-2-羰基- rauwolscine 131-03-3 C21H26N2O3 354.449
    —— (+/-)-3-epi-α-yohimbine 83540-86-7 C21H26N2O3 354.449
    —— acetyl-alloyohimbine 81571-22-4 C23H28N2O4 396.486
    —— (4aS,13bS,14aR)-3,4,4a,5,7,8,13,13b,14,14a-decahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinolin-2(1H)-one 483-29-4 C19H22N2O 294.396

反应信息

点击查看最新优质反应信息

文献信息

  • Procainamide and Quinidine Inhibition of the Human Hepatic Degradation of Meperidine In Vitro
    作者:D. N. Bailey、J. R. Briggs
    DOI:10.1093/jat/27.3.142
    日期:2003.4.1
    Procainamide and quinidine inhibition of the degradation of meperidine in human liver was investigated by incubation of two concentrations of either drug with meperidine in homogenates of human liver over 24 and 36 h. Meperidine concentrations declined by 26% after incubation for 24 h and by 42% after incubation for 36 h. In the presence of procainamide, however, they decreased by only 15% to 18% at 24 h and by only 26% to 28% at 36 h. In the presence of quinidine, they declined by only 18% to 19% at 24 h and by only 27% to 28% at 36 h. Procainamide and quinidine may inhibit human hepatic carboxylesterase hCE-1, which is responsible for catalyzing the hydrolysis of meperidine. This inhibition may prolong the biological half-life of meperidine in patients receiving the drug together with either procainamide or quinidine.
    研究了普鲁卡因酰胺和奎尼丁对人肝脏中美托啡啡降解的抑制作用,方法是将两种药物的两个浓度与美托啡啡在人体肝脏匀浆中孵育24小时和36小时。美托啡啡的浓度在24小时后下降了26%,在36小时后下降了42%。然而,在普鲁卡因酰胺存在下,24小时内仅下降了15%到18%,36小时内仅下降了26%到28%。在奎尼丁的存在下,24小时内仅下降了18%到19%,36小时内仅下降了27%到28%。普鲁卡因酰胺和奎尼丁可能抑制人类肝脏羧酸酯酶hCE-1,该酶负责催化美托啡啡的水解。这种抑制作用可能会延长同时服用普鲁卡因酰胺或奎尼丁的患者体内美托啡啡的生物半衰期。
  • Alkaloids of Rauwolfia nitida root bark
    作者:Mohammed A. Amer、William E. Court
    DOI:10.1016/0031-9422(81)83096-8
    日期:1981.1
    Abstract Thirty-three indole alkaloids were isolated from the root bark of Rauwolfia nitida . Sarpagan, dihydroindole, indolenine, yohimbine, 18-hydroxy-yohimbine ester, heteroyohimbine and anhydronium base types were isolated. The principal alkaloids were reserpine (0.034%), serpentinine (0.033%), pseudoreserpine (0.013%) and reserpiline (0.012%).
    摘要 从萝芙木根皮中分离得到33种吲哚生物碱。分离出 Sarpagan、二氢吲哚、吲哚啉、育亨宾、18-羟基-育亨宾酯、异育亨宾和无水盐碱类型。主要生物碱是利血平 (0.034%)、蛇纹石碱 (0.033%)、假利血平 (0.013%) 和利血平 (0.012%)。
  • Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis
    申请人:ELI LILLY AND COMPANY
    公开号:EP0747049A1
    公开(公告)日:1996-12-11
    This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and either a serotonin agonist or a selective serotonin reuptake inhibitor. This administration may be concurrent or sequential, with either of the two activities being administered first.
    这项发明提供了治疗普通感冒或过敏性鼻炎症状的方法,包括向需要的哺乳动物施用一种缓释肽受体拮抗剂和5-羟色胺激动剂或选择性5-羟色胺再摄取抑制剂的组合。这种给药可以同时进行或顺序进行,两种活性中的任何一种都可以首先给予。
  • COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE
    申请人:Grainger J. David
    公开号:US20080045557A1
    公开(公告)日:2008-02-21
    Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
    提供了分离和纯化的趋化因子肽、变体及其衍生物,以及趋化因子肽类似物。
  • METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE
    申请人:Grainger David J.
    公开号:US20120065401A1
    公开(公告)日:2012-03-15
    Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
    本发明提供了分离和纯化的趋化因子肽、变体和衍生物,以及趋化因子肽类似物。
查看更多